Geode Capital Management
CCCC icon

Geode Capital Management’s C4 Therapeutics CCCC Stock Holding History

Geode Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.5M Sell
951,043
-37,835
-4% -$89.1K ﹤0.01% 3043
2025
Q4 		$1.89M Buy
988,878
+263,574
+36% +$624K ﹤0.01% 3189
2025
Q3 		$1.61M Sell
725,304
-19,749
-3% -$47.4K ﹤0.01% 3256
2025
Q2 		$1.07M Sell
745,053
-685,235
-48% -$997K ﹤0.01% 3305
2025
Q1 		$2.29M Buy
1,430,288
+49,202
+4% +$147K ﹤0.01% 2988
2024
Q4 		$4.97M Buy
1,381,086
+11,410
+0.8% +$56.7K ﹤0.01% 2751
2024
Q3 		$7.81M Buy
1,369,676
+7,460
+0.5% +$44.9K ﹤0.01% 2513
2024
Q2 		$6.29M Buy
1,362,216
+851,901
+167% +$5.08M ﹤0.01% 2599
2024
Q1 		$4.17M Buy
510,315
+28,027
+6% +$217K ﹤0.01% 2795
2023
Q4 		$2.73M Buy
482,288
+26,444
+6% +$60.3K ﹤0.01% 2989
2023
Q3 		$848K Buy
455,844
+16,885
+4% +$51.5K ﹤0.01% 3396
2023
Q2 		$1.21M Sell
438,959
-401,819
-48% -$1.29M ﹤0.01% 3273
2023
Q1 		$2.64M Buy
840,778
+43,486
+5% +$256K ﹤0.01% 2916
2022
Q4 		$4.7M Buy
797,292
+20,070
+3% +$166K ﹤0.01% 2700
2022
Q3 		$6.82M Buy
777,222
+55,797
+8% +$579K ﹤0.01% 2493
2022
Q2 		$5.44M Buy
721,425
+53,606
+8% +$472K ﹤0.01% 2659
2022
Q1 		$16.2M Sell
667,819
-18,357
-3% -$446K ﹤0.01% 2027
2021
Q4 		$22.1M Buy
686,176
+19,853
+3% +$785K ﹤0.01% 1893
2021
Q3 		$29.8M Buy
666,323
+215,781
+48% +$9.24M ﹤0.01% 1699
2021
Q2 		$17M Buy
450,542
+257,950
+134% +$9.24M ﹤0.01% 2080
2021
Q1 		$7.12M Buy
192,592
+3,341
+2% +$133K ﹤0.01% 2593
2020
Q4 		$6.27M Buy
+189,251
New +$5.49M ﹤0.01% 2476

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management's CCCC Position: Q1 2026 in Review

Geode Capital Management reduced its C4 Therapeutics (CCCC) stake by 3.8% in Q1 2026, selling an estimated $89.1K and leaving 951,043 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3043.

Geode Capital Management first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $29.8M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Geode Capital Management held 951,043 shares of C4 Therapeutics worth $2.5M as of Q1 2026.
  • Geode Capital Management sold 37,835 C4 Therapeutics shares in Q1 2026, an estimated $89.1K.
  • C4 Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3043 holding.
  • Geode Capital Management first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Geode Capital Management's C4 Therapeutics position peaked at $29.8M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.